Recent Posts
Deals•Feb 18, 2026
Korsana Raises $150M in Series A to Develop Next‑gen Alzheimer’s Antibody
Korsana, a biotech focused on Alzheimer’s disease, announced a $150 million Series A funding round to advance its next‑generation amyloid‑targeting antibody. The capital will fund clinical development and expansion of its pipeline. Investor identities were not disclosed.
BioSpace
Deals•Feb 4, 2026
PrimeGen US to Merge with DT Cloud Star Acquisition Corp in $1.5B SPAC Deal
California-based biotech PrimeGen US announced a merger with SPAC DT Cloud Star Acquisition Corporation, valuing PrimeGen at approximately $1.5 billion in equity. The transaction, disclosed in a February 4 SEC filing, is expected to close in the second half of 2026 pending...
BioSpace
Deals•Jan 30, 2026
Moderna Partners with Recordati on Rare Disease mRNA Therapy in up to $160M Deal
Moderna and Italy’s Recordati announced a partnership to develop and commercialize mRNA‑3927 for propionic acidemia. Recordati will pay up to $160 million in upfront and milestone payments and receive royalties, while Moderna will lead clinical development and manufacturing and Recordati will...
BioSpace
Deals•Jan 21, 2026
Novo Nordisk Invests in Aspect Biosystems, Expands Partnership to Transfer Cell‑therapy Technologies
Novo Nordisk announced an expanded partnership with Aspect Biosystems, transferring its stem‑cell‑derived islet cell and hypoimmune cell‑engineering technologies. As part of the deal, Novo will make an equity investment and provide research funding to Aspect, though financial terms were not...
BioSpace
Deals•Jan 19, 2026
SpyGlass Pharma and AgomAb Therapeutics Launch Nasdaq IPOs
California‑based SpyGlass Pharma and New York‑based AgomAb Therapeutics announced the launch of their Nasdaq IPOs last week, joining the 2026 IPO class. Both firms have not disclosed the amount they expect to raise. SpyGlass will list on the Nasdaq Global Select...
BioSpace
Deals•Jan 8, 2026
Eli Lilly to Acquire Ventyx Biosciences for $1.2B
Eli Lilly announced a $1.2 billion cash acquisition of California‑based Ventyx Biosciences, gaining its oral drug pipeline targeting inflammatory diseases. The deal, expected to close in the first half of 2026 pending approvals, expands Lilly’s portfolio beyond its obesity drugs.
BioSpace
News•Jan 7, 2026
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
BioSpace’s 2026 NextGen list spotlights 15 early‑stage life‑science startups that secured seed or Series A financing despite a 2025 capital crunch. The cohort includes rare‑disease pioneers and innovators tackling cardiovascular, oncology, and genetic therapies. Notable deals feature Light Horse’s $62 million Series A...
By BioSpace
Deals•Jan 7, 2026
Corsera Raises $80M as First Preventative Heart Disease Program Moves Into Clinic
Cardiovascular biotech Corsera Health announced an $80 million Series A round co‑led by Forbion and Population Health Partners to advance its siRNA therapeutics, including the COR‑1004 program now entering Phase I trials. The funding will support the development of AI‑enabled tools for ASCVD...
BioSpace
Deals•Jan 7, 2026
Crinetics Pharmaceuticals Announces $350M Public Offering
Crinetics Pharmaceuticals announced a $350 million public offering of 7.6 million shares, with an underwriters’ option for an additional $52 million, to fund the development of its atumelnant drug after strong Phase II results that outperformed Neurocrine’s Crenessity. The offering was announced on Monday,...
BioSpace
Deals•Jan 7, 2026
Amgen to Acquire Dark Blue Therapeutics for Up to $840M
Amgen announced on Tuesday that it will acquire England‑based Dark Blue Therapeutics in a deal valued at up to $840 million, aiming to bolster its oncology pipeline with Dark Blue’s pre‑clinical protein‑degradation assets. The acquisition will integrate Dark Blue into Amgen’s...
BioSpace
News•Jan 6, 2026
Deep Dive: Huntington’s at a Crossroads
The neuro‑degenerative field has gained momentum with recent disease‑modifying approvals, and uniQure’s September data showed its gene therapy could slow Huntington’s progression by 75%. However, the FDA signaled that the Phase I/II results may not satisfy the evidentiary standards for...
By BioSpace
News•Jan 6, 2026
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study
Arrowhead Pharma reported that its RNAi drug ARO‑INHBE, combined with Eli Lilly’s tirzepatide, produced roughly double the weight loss seen with tirzepatide alone in a small Phase I/IIa study. In the interim analysis, patients receiving the combo lost 9.4% of body weight...
By BioSpace
News•Jan 6, 2026
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
Eli Lilly has struck a new multi‑year collaboration with Nimbus Therapeutics, paying $55 million upfront for a preclinical oral obesity drug program that could generate up to $1.3 billion in milestones. The partnership leverages Nimbus’s AI‑driven, structure‑based design to discover small‑molecule treatments for...
By BioSpace